Premium
Prenatal trisomy 21 screening using the Lens culinaris agglutinin‐reactive alpha‐fetoprotein ratio
Author(s) -
Yamamoto Ritsu,
Minobe Shinichiro,
Ebina Yasuhiko,
Watari Hidemichi,
Kudo Masataka,
Henmi Fumiyo,
Satomura Shinji,
Fujimoto Seiichiro,
Minakami Hisanori,
Sakuragi Noriaki
Publication year - 2004
Publication title -
congenital anomalies
Language(s) - English
Resource type - Journals
eISSN - 1741-4520
pISSN - 0914-3505
DOI - 10.1111/j.1741-4520.2004.00013.x
Subject(s) - trisomy , alpha fetoprotein , medicine , obstetrics , biology , genetics , hepatocellular carcinoma
For the purpose of improving the clinical efficacy of alpha‐fetoprotein (AFP)‐L3% in prenatal screening for trisomy 21, we calculated the multiple of the median (MoM) of AFP‐L3% (L3 MoM) and the ratio of L3 MoM to AFP MoM (L3 MoM/AFP MoM) in maternal serum. Maternal serum samples from 1822 women (maternal age 37.3 ± 3.8 years, and weeks of gestation 16.0 ± 1.0; mean ± SD) with unaffected pregnancies and 28 women (37.6 ± 4.6 years, 16.6 ± 3.1) pregnant with of trisomy 21 fetuses were obtained. The AFP concentration and AFP‐L3% in maternal serum were measured using a liquid‐phase binding assay. The areas under the receiver operating characteristic curves (AUCs) of AFP MoM, AFP‐L3%, L3 MoM, and L3 MoM/AFP MoM were 0.750, 0.868, 0.949 and 0.946, respectively. The AUCs of L3 MoM and L3 MoM/AFP MoM were significantly higher than AFP‐L3% ( P < 0.05) and AFP MoM ( P < 0.0005). However, no statistical difference was observed between the AUCs of L3 MoM and L3 MoM/AFP MoM. In conclusion, the L3 MoM should be an effective replacement for AFP‐L3% in prenatal trisomy 21 screening.